In a groundbreaking study that could reshape our understanding of liver metabolism and hormonal regulation, researchers have uncovered a novel, non-enzymatic role for neuraminidase 1 (NEU1) in controlling the hepatic response to glucagon in mice. This discovery not only challenges traditional perceptions of NEU1 as merely an enzyme involved in desialylation processes but also opens new avenues for therapeutic interventions targeting metabolic diseases such as diabetes and non-alcoholic fatty liver disease (NAFLD).
Neuraminidases are commonly known as enzymes that remove sialic acid residues from glycoproteins and glycolipids, playing critical roles in cellular signaling and membrane dynamics. Among the four mammalian neuraminidases, NEU1 has been extensively characterized for its enzymatic activity within lysosomes, traditionally implicated in the catabolism of sialoglycoconjugates. However, the study led by Sun, Zhu, Wu, and colleagues, recently published in Nature Communications, reveals that NEU1 possesses a significant non-enzymatic function that modulates hepatic glucagon signaling — a mechanism crucial for maintaining glucose homeostasis under fasting conditions.
Glucagon, secreted by pancreatic alpha cells in response to hypoglycemia or fasting, orchestrates a complex cascade of intracellular events that promote gluconeogenesis and glycogenolysis in the liver. These processes ensure adequate glucose supply to peripheral tissues during periods of caloric deprivation. Dysregulation of hepatic glucagon response is a hallmark of type 2 diabetes and insulin resistance, leading to inappropriate hyperglycemia. Therefore, finely tuned regulatory mechanisms exist to balance glucagon’s effects and maintain metabolic homeostasis.
The researchers employed sophisticated genetic and biochemical analyses to identify that NEU1, independent of its enzymatic activity, interacts with specific membrane-associated protein complexes within hepatocytes, thereby restraining the downstream signaling of the glucagon receptor. This interaction appears to dampen the production of cyclic AMP (cAMP), a pivotal second messenger that amplifies glucagon signals leading to glucose output. Loss of NEU1 expression or its non-enzymatic function resulted in exaggerated hepatic glucagon responses, culminating in elevated glucose production and systemic glucose imbalance in murine models.
These findings highlight that NEU1 functions beyond its classical enzymatic role, acting as an intrinsic modulator of glucagon receptor-mediated pathways. The precise molecular interface involves NEU1’s cytoplasmic domain, which was previously considered a structural segment without functional significance. By interfering with receptor-proximal signaling complexes, NEU1 effectively tempers the liver’s glucose-generating pathways, providing a previously unrecognized layer of metabolic regulation.
The implications of this work extend to several facets of metabolic research and therapeutic strategy development. For decades, the pharmacological modulation of glucagon signaling has presented formidable challenges due to the receptor’s widespread physiological roles and the complexity of downstream effects. Targeting NEU1’s non-enzymatic function may offer a more nuanced approach, potentially allowing selective attenuation of hepatic glucagon response without disrupting systemic hormone regulation.
Further, this study prompts a re-evaluation of the non-catalytic roles of other neuraminidases and lysosomal enzymes which might contribute to diverse cellular functions through protein-protein interactions. The paradigm shift toward considering multifunctional characteristics of these proteins could unveil novel regulatory networks in cellular metabolism and signal transduction.
The experimental approach integrated multiple technological advancements, including CRISPR-Cas9 mediated gene editing to generate hepatocyte-specific NEU1 mutants deficient in enzymatic activity but retaining structural integrity. This strategy enabled the differentiation of enzymatic versus non-enzymatic functions within living organisms. Additionally, state-of-the-art proteomic profiling and live-cell imaging substantiated the dynamic interactions between NEU1 and glucagon receptor signaling complexes at the plasma membrane, shedding light on mechanistic nuances at molecular resolution.
Intriguingly, the study noted that under physiological fasting conditions, the expression of NEU1 is upregulated in hepatic tissue, suggesting an adaptive mechanism to prevent hyperactivation of glucagon pathways and maintain glucose balance. This adaptive response may become compromised in metabolic disorders, implying that NEU1 modulation could be a compensatory target in disease states.
The discovery also intersects with broader themes in endocrinology and liver physiology, particularly regarding how intracellular lysosomal components influence surface receptor signaling and metabolic flux. The NEU1-glucagon receptor axis exemplifies the intricate crosstalk between organelles and membrane domains, underscoring the complexity of cellular metabolic regulation far beyond canonical signaling schemes.
Looking forward, the translation of these findings into clinical applications will necessitate the development of molecular tools to specifically manipulate NEU1’s non-enzymatic function without affecting its enzymatic role, preserving overall cellular homeostasis. Small-molecule modulators or peptide mimetics that replicate NEU1’s inhibitory interactions with glucagon receptor complexes could represent promising therapeutic candidates for ameliorating hepatic glucose overproduction in diabetes.
Moreover, as the liver plays a central role in systemic metabolism, the impact of NEU1’s action may extend to cross-organ communication networks. Investigating whether NEU1-mediated restraint of glucagon response influences lipid metabolism, inflammatory pathways, and energy homeostasis warrants comprehensive future research.
This pioneering work by Sun et al. not only redefines the functional landscape of neuraminidase 1 but also enriches our conceptual framework of hormone-mediated metabolic control. By revealing a sophisticated molecular brake on glucagon signaling within hepatocytes, the study opens up exciting possibilities for targeted intervention in metabolic diseases, potentially revolutionizing current therapeutic paradigms.
In conclusion, the identification of NEU1’s non-enzymatic role in tempering hepatic glucagon response marks a significant advancement in metabolic biology. This novel mechanism underscores the multi-dimensional capabilities of conventional enzymes, emphasizing their involvement in structural and regulatory roles beyond catalysis. As science continues to peel back layers of cellular complexity, discoveries like these pave the way for innovative strategies to tackle some of the most pressing health challenges worldwide.
Subject of Research: The study focuses on the non-enzymatic role of neuraminidase 1 (NEU1) in regulating hepatic glucagon response in mice, providing new insight into liver metabolism and hormone signaling pathways.
Article Title: A non-enzymatic function of neuraminidase 1 restrains hepatic glucagon response in mice.
Article References:
Sun, XM., Zhu, LZ., Wu, GD. et al. A non-enzymatic function of neuraminidase 1 restrains hepatic glucagon response in mice. Nat Commun (2026). https://doi.org/10.1038/s41467-026-72630-2
Image Credits: AI Generated
